

Gilead Fund Commentary

June 30, 2024

AT A GLANCE

Managers: Finny Kuruville, MD, PhD;
Anant Goel

*Effective 07/16/2024 Anant Goel will no longer serve as a
Co-Portfolio Manager for the Fund*

Fund Objective: Seeks to provide long-term capital appreciation.

About the Fund: A diversified mutual fund representing our “best ideas” for long-term capital appreciation. Historical emphases in small- and mid-cap growth, Health Care and Information Technology.

Benchmark: Bloomberg US Mid Cap Growth Index

Secondary Benchmark: Russell Midcap Growth Index

Morningstar Category: US Fund Mid-Cap Growth

Lipper Category: Mid-Cap Growth

Net Assets: \$3.35 billion

Inception Date: July 8, 2008

Eventide Asset Management, LLC
One International Place, Suite 4210
Boston, MA 02110
877-771-EVEN (3836)
WWW.EVENTIDEFUNDS.COM

Class I: ETILX | Class A: ETAGX | Class C: ETCGX | Class N: ETGLX

Review

In the second quarter of 2024, the Gilead Fund (Class I)¹ achieved a -7.35% return, contrasting with the Bloomberg US Midcap Growth Index’s -4.39%. The fund’s lag to the Bloomberg US Midcap Growth index primarily stemmed from underperformance in the Financials and Consumer Discretionary sectors, while we noted outperformance in the Energy and Materials sectors.

Contributors

Top Five Contributors² (%)

Q2 2024

Company	Ticker	Sector	Average Weight	Contribution to Return	Total Return ³
TransMedics Group Inc	TMDX	Health Care	3.04	1.84	103.71
Guardant Health Inc	GH	Health Care	1.62	0.58	39.99
Trane Technologies PLC	TT	Industrials	5.50	0.49	9.86
CrowdStrike Holdings Inc	CRWD	Information Technology	2.27	0.43	19.53
Mirum Pharmaceuticals Inc	MIRM	Health Care	1.13	0.40	36.11

In the second quarter of 2024, the largest positive contributors to performance were: TransMedics Group Inc, Guardant Health Inc, Trane Technologies PLC, CrowdStrike Holdings Inc, and Mirum Pharmaceuticals Inc. TransMedics Group, a provider of therapy for end-stage organ failure, continued their trajectory of strong execution and provided timelines on pipeline initiatives. Guardant Health, which provides cell diagnostics for cancer patients, had a positive Advisory Committee meeting complemented by strong core business execution. Trane Technologies PLC, a provider of HVAC systems for energy efficiency and reduced carbon emissions, continued to post strong results in its commercial HVAC business, driven by data centers, education, and healthcare. CrowdStrike Holdings Inc, an enterprise cybersecurity platform to prevent endpoint attacks, continued their cadence of strong execution in a difficult demand market. Mirum Pharmaceuticals, which treats rare pediatric cholestasis diseases with IBAT inhibitors, disclosed positive clinical updates for an important pipeline asset.

Detractors

Top Five Detractors² (%)

Q2 2024

Company	Ticker	Sector	Average Weight	Contribution to Return	Total Return ³
Flywire Corp	FLYW	Financials	1.80	-0.78	-33.94
Xometry Inc	XMTR	Industrials	2.28	-0.82	-31.56
Coursera Inc	COUR	Consumer Discretionary	1.04	-0.88	-46.15
DoubleVerify Holdings Inc	DV	Information Technology	1.39	-0.94	-44.62
Zentalis Pharmaceuticals	ZNTL	Health Care	1.54	-1.57	-74.05

In the second quarter of 2024, the largest negative detractors to performance were: Flywire Corp, Xometry Inc, Coursera Inc, DoubleVerify Holdings Inc, and Zentalis Pharmaceuticals. Flywire Corp, a global payments enablement software provider for education and healthcare, continues to execute well, but new Canadian visa regulation created shorter term uncertainty on revenues from Canada. Xometry Inc, an AI-enabled marketplace for on-demand manufacturing, experienced a sell off due to sentiment in short cycle manufacturing being hurt in part due to weaker ISM manufacturing numbers. Coursera Inc, a provider of online education services, saw poor execution in Q1 leading to the company selling off. DoubleVerify

Performance is historical and does not guarantee future results.

Portfolio Team Outlook

Eventide seeks to own companies that create compelling value for the global common good. The Gilead fund seeks to accomplish this with an emphasis on small and mid cap companies, with a particular focus on healthcare and technology.

During the second quarter, Gilead underperformed the benchmark due to stock selection. While the performance was challenged, many of the companies we own continue to execute well and see growth in their businesses. The stocks of several holdings in our portfolio have underperformed, in part because they are solving complex problems that require years of effort and significant capital. These types of companies are particularly sensitive to rising interest rates because their cash flows are expected to come in the future.

The Gilead Fund is focused on finding great long-term investment opportunities, often

found in healthcare and biotechnology. We believe that these areas will be the mega-trend of the century. Just as Artificial Intelligence (AI) has propelled the largest tech companies to new heights, we also expect AI to have a transformative impact on biotechnology research and development in the years to come. Yet the S&P Biotechnology Select Industry Index, which represents the biotechnology sub-industry portion of the S&P Total Markets Index, posted negative returns in the second quarter, while its valuation remains proportionately similar to what it was five years ago.

A potential turn in interest rates may serve as a catalyst for many of our investments. We believe a change in direction, lowering rates, would likely convert headwinds into tailwinds for many of the companies we invest in. We remain confident in our



Finny Kuruville, MD, PhD
Co-Chief Investment Officer,
Senior Portfolio Manager

investment strategy because we believe that intrinsic valuations are attractive for many of our holdings. While we are mindful of the risk of rising rates, we consider it an unlikely scenario at this point.

Our investment strategy is anchored in the belief that companies with sustainable competitive advantages in attractive industries, run by great management teams focused on value creation for their stakeholders, generate better long-term risk-adjusted returns.

Holdings, a digital media and analytics tools provider, saw a handful of top customers pull in spend in Q1, which led the company to reduce full year guidance, adding to investor fears of structural challenges in the verification space. Zentalis Pharmaceuticals, a biotechnology company focused on novel small molecule therapies, announced that FDA has placed a partial clinical hold on their ongoing trials.

Trailing Returns⁴ (%)

30 Jun 2024

	YTD	3-mos	1-year	3-year ⁵	5-year ⁵	10-year ⁵	Since Inception ⁵	Inception Date
<i>Eventide Gilead Fund</i>								
Class I	-4.61	-7.35	-0.40	-7.96	6.41	9.53	13.01	02/02/2010
Class A without load	-4.74	-7.42	-0.66	-8.19	6.15	9.25	13.85	10/28/2009
Class A with 5.75% load ⁶	-10.22	-12.74	-6.38	-9.98	4.90	8.61	13.40	10/28/2009
Class C ⁷	-5.10	-7.58	-1.39	-8.88	5.35	8.43	12.99	10/28/2009
Class N	-4.73	-7.40	-0.62	-8.15	6.20	9.30	12.51	07/08/2008
<i>Benchmarks</i>								
Bloomberg US Mid Cap Growth Index ⁸	4.21	-4.39	11.87	0.71	10.01	10.08	10.25	07/08/2008
Russell Midcap Growth Index ⁸	5.98	-3.21	15.05	-0.08	9.93	10.51	10.74	07/08/2008
S&P 500 Total Return Index ⁸	15.29	4.28	24.56	10.01	15.05	12.86	11.73	07/08/2008

Performance is historical and does not guarantee future results. Investment return and principal value will fluctuate with changing market conditions so that when redeemed, shares may be worth more or less than their original cost. Current performance may be lower or higher than the data quoted. Investors cannot directly invest in an index, and unmanaged index returns do not reflect any fees, expenses, or sales charges. The volatility of an index may be materially different than that of the Fund, and investors should not expect the Fund to achieve the same results as a listed index. Performance data current to the most recent month-end may be obtained by calling 1-877-771-EVEN (3836).

Eventide Gilead Fund gross expenses: Class I: 1.18%; Class A: 1.43%; Class C: 2.18%; Class N: 1.38%.

1. Prior to Q4 2020, Class N shares were displayed.
2. Source: Bloomberg PORT Attribution Report. Allocation percentages are subject to change at any time, and should not be considered investment advice.
3. The total return percentage listed is impacted by the Fund's transactions and transacted price levels of the holding during the quarter.

4. The returns shown do not reflect the deduction of taxes that a shareholder would pay on fund distributions or on the redemption of fund shares. Because of ongoing market volatility, fund performance may be subject to substantial short-term changes.
5. Performance figures for periods greater than 1 year are annualized. The indices use an inception date of 07/08/2008.
6. In the case of investments at or above the \$1 million breakpoint (where you do not pay an initial sales charge), a 1.00% contingent deferred sales charge ("CDSC") may be assessed on shares redeemed within eighteen months of purchase. The CDSC for these Class A shares is based on the NAV at the time of purchase. The holding period for the CDSC begins on the day you buy your shares. Some intermediaries may waive or discount the CDSC under certain circumstances.
7. A 1.00% contingent deferred sales charge ("CDSC") may be assessed on C-shares redeemed within twelve months of purchase.
8. On 06/30/2024, the Fund's primary benchmark to compare its performance changed from the Russell Midcap Growth Index to the Bloomberg US Mid Cap Growth Index because the Fund's Adviser believes it provides more value per cost while maintaining high standards of accuracy, relevance, and reliability. On 04/01/2023 the Fund's primary benchmark to compare its performance was changed from the S&P 500 Total Return Index to the Russell Midcap Growth Index because the Fund's Adviser believes it is more reflective of the Fund's portfolio. The Bloomberg US Mid Cap Growth Index is a float market-cap-weighted index based on an equal-weighted combination of four factors: earnings yield, valuation, dividend yield, and growth. The constituents consist of the lower 800 in capitalization of the Bloomberg 1000 Index, which is a float market-cap-weighted benchmark of the 1000 most highly capitalized US companies. Source: Bloomberg Index Services Limited. Bloomberg® is a trademark and service mark of Bloomberg Finance L.P. and its affiliates (collectively "Bloomberg"). Bloomberg or Bloomberg's licensors own all proprietary rights in the Bloomberg Indices. Neither Bloomberg nor Bloomberg's licensors approves or endorses this material, or guarantees the accuracy or completeness of any information herein, or makes any warranty, express or implied, as to the results to be obtained therefrom and, to the maximum extent allowed by law, neither shall have any liability or responsibility for injury or damages arising in connection therewith. The Russell Midcap Growth Index measures the performance of the U.S. equity mid-cap growth segment. The S&P 500 is an index created by Standard & Poor's of American stocks with the largest market capitalization.

The opinions expressed herein are those of the Fund's portfolio management team as of 06/30/2024 and are subject to change. There is no guarantee that such views are correct or that the outlook opinions will come to pass. Specific companies mentioned are for performance attribution informational purposes only and should not be construed as buy or sell advice. Reliance upon the views expressed herein is at the sole discretion of the reader. The Adviser's judgment about the quality and intrinsic value of companies may prove to be incorrect. There is no guarantee that any investment will achieve its objectives, generate positive gains, or avoid losses.

Mutual funds involve risk including the possible loss of principal. Past performance does not guarantee future results. *The Fund's ethical values screening criteria could cause it to under-perform similar funds that do not have such screening criteria. The Fund can invest in smaller-sized companies which may experience higher failure rates than larger companies and normally have a lower trading volume than larger companies. The Fund can have risk associated with the biotechnology and pharmaceutical industry in which these companies may be heavily dependent on clinical trials with uncertain outcomes and decisions made by the U.S. Food and Drug Administration. Companies in the technology industries have different risks including but not limited to products becoming obsolete, and entrance of competing products. Companies in the Industrial Sector carry various risks including, but not limited to, risk related to debt loads, intense competition, and sensitivity to economic cycles. The Fund can have risk related to option investing. There are special risks associated with investments in foreign companies including exposure to currency fluctuations, less efficient trading markets, political instability and differing auditing and legal standards. The Fund can invest in private companies. Private investments include various risks including but not limited to lack of liquidity, capital commitment risk, and valuation risk. Private companies may not be financially profitable and have uncertain futures, subjecting them to additional risks.*

This information is for use with concurrent or prior delivery of a fund prospectus, which can be obtained at <https://www.eventidefunds.com/prospectus> or by calling 1-877-771-EVEN (3836). Investors should consider a fund's investment objectives, risks, charges and expenses carefully before investing or sending money. Eventide Mutual Funds are distributed by Northern Lights Distributors, LLC, Member FINRA/SIPC, which is not affiliated with Eventide Asset Management, LLC.